The Pharmacological Approach of Behavioral Disturbances in Dementia

Journal of Pharmacy Practice

Volumn 17, Issue 2, 2004, Pages 129-132

  Maher Jr , Robert L ^a,b  

^a DUQUESNE UNIVERSITY   (United States)

^b Clin Serv at Prof Spec Pharmac   (United States)

Author keywords

Behavioral disturbances; Dementia; Elderly

Indexed keywords

ACETOPHENAZINE; ACETOPHENAZINE DIMALEATE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CHLORPROMAZINE; CHLORPROTHIXENE; CITALOPRAM; CLOZAPINE; HALOPERIDOL; LORAZEPAM; LOXAPINE; LOXAPINE SUCCINATE; MESORIDAZINE; MESORIDAZINE BESYLATE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; OXAZEPAM; PAROXETINE; PERPHENAZINE; PROCHLORPERAZINE; PROCHLORPERAZINE MALEATE; PROMAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; TIOTIXENE; TRIFLUPROMAZINE; UNINDEXED DRUG;

AGGRESSION; AGITATION; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; BEHAVIOR DISORDER; BODY WEIGHT DISORDER; CAREGIVER; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; DELUSION; DEMENTIA; DEPRESSION; DISEASE EXACERBATION; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; MENTAL DISEASE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARANOIA; REVIEW; SEDATION; SEXUAL BEHAVIOR; SIDE EFFECT; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; TREATMENT OUTCOME; VERBAL BEHAVIOR; VOMITING;

EID: 1642306353     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1177/0897190004263316     Document Type: Review

References (33)

1. American Psychiatric Association Workgroup on Alzheimer's Disease and Related Disorders. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatr. 1997;154(suppl.):1-39.
2. Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990;38:553-563.
3. Schneider LS, Sobin PB. Non-neuroleptic treatment of behavioral symptoms and agitation in Alzheimer's disease and other dementia. Psychopharmacol Bull. 1992;28:71-79.
4. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry. 2001;9:361-381.
5. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidenced-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154-1166.
6. Lebowitz BD, Pearson JL, Schneider LS, et al. Diagnosis and treatment of depression in late life: consensus statement update. JAMA. 1997;278:1186-1190.
7. Alexopoulos GS, Katz IR, Reynolds CF, et al. Pharmacotherapy of depressive disorders in older patients. Postgrad Med Spec Rep. 2001;10:1-88.
8. Datto CJ, Oslin DW, Streim JE, et al. Pharmacologic treatment of depression in nursing home residents: a mental health services perspective. J Geriatr Psychiatry Neurol. 2002;15:141-146.
9. Katz IR, Simpson GM, Curlik SM, et al. Pharmacologic treatment of major depression for elderly patients in residential care settings. J Clin Psychiatry 1990;51(suppl.):41-47.
10. Streim JE, Oslin DW, Katz IR, et al. Drug treatment of depression in frail elderly nursing home residents. Am J Geriatr Psychiatry. 2000;8:150-159.
11. Magai C, Kennedy G, Cohen CI, et al. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. Am J Geriatr Psychiatry. 2000;8:66-74.
12. Beck CK, Vogelpohl TS, Rasin JH, et al. Effects of behavioral interventions on disruptive behavior and affect in demented nursing home residents. Nurs Res. 2002;51:219-228.
13. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry. 1999;60:107-115.
14. Stotsky B. Multicenter study comparing thioridazine with diazepam and placebo in elderly, nonpsychotic patients with emotional and behavioral disorders. Clin Ther. 1984;6:546-559.
15. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946-955.
16. Clark WS, Street JS, Feldman PD, et al. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's. Dis J Clin Psychiatry. 2001;62:34-40.
17. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities. Arch Gen Psychiatry. 2000;57:968-976.
18. Barnes R, Veith R, Okimoto J, et al. Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. Am J Psychiatry. 1982;139:1170-1174.
19. Goldberg RJ, Goldberg J. Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience. Int Psychogeriatr. 1997;9:65-68.
20. Coccaro EF, Kramer E, Zemishlany Z, et al. Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. Am J Psychiatry 1990;147:1640-1645.
21. Tariot PN, Ismail MS. Use of quetiapine in elderly patients. Jour of Clinl Psych. 2003;63 Suppl 13:21-6.
22. Covington JS. Alleviating agitation, apprehension, and related symptoms in geriatric patients: a double-blind comparison of a phenothiazine and a benzodiazepine. South Med J. 1975;68:719-724.
23. Christensen DB, Benfield WR. Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients. J Am Geriatr Soc. 1998;46:620-625.
24. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. Br J Psychiatry. 1990;157:894-901.
25. Ramadan FH, Naughton BJ, Bassanelli AG. Treatment of verbal agitation with a selective serotonin reuptake inhibitor. J Geriatr Psychiatry Neurol. 2000;13:56-59.
26. Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155:54-61.
27. Lott AD, McElroy SL, Keys MA. Valproate in the treatment of behavioral agitation in elderly patients with dementia. J Neuropsychiatry Clin Neurosci. 1995;7:314-319.
28. Marshall LL, Miller SW. Divalproex sodium for the behavioral manifestations of Alzheimer's disease. Consult Pharm. 2001;16:758-766.
29. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc. 2001;49:1590-1599.
30. Cantillon M, Brunswick R, Molina D, et al. Buspirone vs. haloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer's disease. Am J Geriatr Psychiatry. 1996;4:263-267.
31. Paleacu D, Mazeh D, Mirecki I, Even M, Barak Y. Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease. Clin Neuropharm. 2002;25:313-317.
32. Rosler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract 2002;127:20-36.
33. Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc. 2003;51:1305-1317.